Your session is about to expire
← Back to Search
Other
MT1002 for Injection for Heart Attack
Phase 1
Waitlist Available
Research Sponsored by Shaanxi Micot Technology Limited Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
No Placebo-Only Group
Summary
This trial tests MT1002, an injection that prevents blood clots, in patients with heart issues and kidney problems, as well as healthy volunteers. It aims to see if the medication works safely and effectively in these groups.
Eligible Conditions
- Heart Attack
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Plasma PK
Urine PK
plasma PK
Secondary study objectives
Adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Renal impairmentExperimental Treatment1 Intervention
moderate and severe Renal impairment subjects
Group II: Healthy controlExperimental Treatment1 Intervention
Healthy control subjects with normal renal function
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Shaanxi Micot Technology Limited CompanyLead Sponsor
6 Previous Clinical Trials
268 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger